Rhabdomyolysis Associated With Pomegranate Juice Consumption

      This 48-year-old man with possible underlying myopathy was successfully treated with ezetimibe 10 mg/day and rosuvastatin 5 mg every other day for 17 months. Three weeks before presentation, he began drinking pomegranate juice (200 ml twice weekly). He presented urgently with thigh pain and an elevated serum creatine kinase level (138,030 U/L, normal <200 U/L). In conclusion, because both grapefruit and pomegranate juice are known to inhibit intestinal cytochrome P450 3A4, this report suggests that pomegranate juice may increase the risk of rhabdomyolysis during rosuvastatin treatment, despite the fact that rosuvastatin is not known to be metabolized by hepatic P450 3A4.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Karch A.M.
        The grapefruit challenge.
        Am J Nurs. 2004; 104: 33-35
        • Hidaka M.
        • Okumura M.
        • Fujita K.
        • Ogikubo T.
        • Yamasaki K.
        • Iwakiri T.
        • Setoguchi N.
        • Arimori K.
        Effects of pomegranate juice on human cytochrome p450 3A (CYP3A) and carbamazepine pharmacokinetics in rats.
        Drug Metab Dispos. 2005; 33: 644-648
      1. The new juice in town.
        Consumer Reports. 2005; : 1-4
        • Bailey D.G.
        • Malcolm J.
        • Arnold O.
        • Spence J.D.
        Grapefruit juice-drug interactions.
        Br J Clin Pharmacol. 1998; 46: 101-110
        • Bailey D.G.
        • Malcolm J.
        • Arnold O.
        • Spence J.D.
        Grapefruit juice-drug interactions.
        Br J Clin Pharmacol. 2004; 58: S831-S840
        • Greenblatt D.J.
        • von Moltke L.L.
        • Harmatz J.S.
        • Chen G.
        • Weemhoff J.L.
        • Jen C.
        • Kelley C.J.
        • LeDuc B.W.
        • Zinny M.A.
        Time course of recovery of cytochrome p450 3A function after single doses of grapefruit juice.
        Clin Pharmacol Ther. 2003; 74: 121-129
        • McTaggart F.
        • Buckett L.
        • Davidson R.
        • Holdgate G.
        • McCormick A.
        • Schneck D.
        • Smith G.
        • Warwick M.
        Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.
        Am J Cardiol. 2001; 87: 28B-32B